A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease

L. M. Refolo, M. A. Pappolla, J. LaFrancois, B. Malester, S. D. Schmidt, T. Thomas-Bryant, G. S. Tint, R. Wang, M. Mercken, S. S. Petanceska, K. E. Duff

Research output: Contribution to journalArticlepeer-review

492 Scopus citations

Abstract

Clinical, epidemiological, and laboratory studies suggest that cholesterol may play a role in the pathogenesis of Alzheimer's disease (AD). Transgenic mice exhibiting an Alzheimer's β-amyloid phenotype were treated with the cholesterol-lowering drug BM15.766 and tested for modulation of β-amyloid levels. BM15.766 treatment reduced plasma cholesterol, brain Aβ peptides, and β-amyloid load by greater than twofold. A strong, positive correlation between the amount of plasma cholesterol and Aβ was observed. Furthermore, drug treatment reduced the amyloidogenic processing of the amyloid precursor protein, suggesting alterations in processing in response to cholesterol modulation. This study demonstrates that hypocholesterolemia is associated with reduced Aβ accumulation suggesting that lowering cholesterol by pharmacological means may be an effective approach for reducing the risk of developing AD.

Original languageEnglish (US)
Pages (from-to)890-899
Number of pages10
JournalNeurobiology of Disease
Volume8
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

ASJC Scopus subject areas

  • Neurology

Fingerprint

Dive into the research topics of 'A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this